Integra LifeSciences Holdings Corp (IART) KPIs and segments
Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –
KPIs & segments
Operating metrics and segments that drive Integra LifeSciences's business
Integra LifeSciences's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Specialty Surgery($M)5 | 304 | 309 | 283 | 323 | 293 | 304 | 281 | 315 | 271 | 302 | 256 | 272 | |
Neurosurgery($M) | 214 | 213 | 198 | 226 | 202 | 209 | 191 | 220 | 176 | 206 | 202 | 210 | |
Surgical Instruments($M) | 49.7 | 54.8 | 50.2 | 53.1 | |||||||||
Instruments($M) | 47.2 | 52.3 | 50.2 | 53.1 | 51.0 | 51.0 | 54.2 | 54.5 | 44.4 | 51.1 | |||
ENT Solutions($M) | 40.4 | 41.2 | 40.9 | 41.9 | |||||||||
ENT($M) | 37.7 | 44.8 | 40.9 | 41.9 | 38.8 | 43.5 | 40.6 | 41.7 | 9.79 | 10.3 | |||
Tissue Technologies($M)2 | 112 | 109 | 112 | 102 | 128 | 110 | 116 | 112 | 125 | ||||
Wound Reconstruction and Care($M) | 80.0 | 84.0 | 84.7 | 74.8 | 102 | 80.5 | 87.7 | 80.9 | 93.9 | ||||
Private Label($M) | 31.6 | 25.5 | 26.9 | 27.2 | 26.5 | 29.6 | 28.7 | 31.6 | 31.6 | ||||
Tissue Reconstruction($M)4 | 107 | 109 | 109 | 109 | 112 | 102 | |||||||
Wound Reconstruction Solutions($M) | 81.5 | 81.3 | 84.0 | 84.7 | |||||||||
Wound Reconstruction and Care($M) | 79.6 | 74.8 | |||||||||||
Private Label($M) | 28.2 | 29.1 | 26.9 | 27.2 | |||||||||
Corporate Partnerships($M) | 25.5 | 25.5 | |||||||||||
United States($M) | 299 | 307 | 289 | 320 | 296 | 306 | 282 | 336 | 290 | 310 | 256 | 283 | |
Asia Pacific($M) | 47.9 | 48.7 | 45.2 | 53.7 | 42.7 | 47.7 | 45.1 | 44.1 | 37.1 | 46.0 | 49.5 | 46.1 | |
Europe($M) | 42.3 | 42.6 | 40.0 | 41.9 | 42.9 | 42.6 | 35.3 | 41.8 | 34.4 | 40.7 | 41.6 | 45.2 | |
Rest of World($M) | 21.6 | 20.4 | 17.4 | 19.0 | 20.6 | 19.0 | 20.0 | 20.7 | 19.2 | 21.3 | 21.5 | 22.6 | |
Specialty Surgery($M) | 90.8 | 88.9 | 83.1 | 143 | 88.8 | -302 | 72.2 | 136 | 101 | 164 | 103 | 118 | |
Tissue Technologies($M) | 30.1 | 27.1 | -105 | 16.0 | 42.8 | 28.5 | 37.2 | 30.7 | 41.9 | ||||
Tissue Reconstruction($M) | 15.5 | 18.9 | 20.3 | 11.4 | -119 | 4.44 | |||||||
Specialty Surgery($M) | 177 | 179 | 173 | 213 | 179 | 184 | 171 | 212 | 175 | 209 | 163 | ||
Tissue Technologies($M) | 69.1 | 66.8 | 60.9 | 56.9 | 85.0 | 69.5 | 75.0 | 74.9 | |||||
Tissue Reconstruction($M) | 65.3 | 67.5 | 71.3 | 60.5 | 55.0 | 52.7 | |||||||
28 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-23.
See a number that looks wrong?